Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Barchart Premier: The most comprehensive method for keeping track of all your investments. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Bionxt Solutions Inc. (BNXT.CN)

Bionxt Solutions Inc. (BNXT.CN)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [CNSX]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [CNSX]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
BioNxt Reports “Intention to Grant” Patent Notification from the European Patent Office for Its Oral Cladribine Sublingual Thin-Film as the Multiple Sclerosis Market Shifts Toward Patient-Friendly Therapies

VANCOUVER, BC / November 4, 2025 / BioNxt Solutions Inc. (“BioNxt” or the “Company”) (CSE:BNXT)(OTCQB:BNXTF)(FSE:BXT) is pleased to announce that its wholly owned German subsidiary, Vektor Pharma...

BNXT.CN : 0.5700 (-3.39%)
BNXTF : 0.4305 (-5.45%)
BioNxt Reports “Readiness to Grant” Patent Notification from the Eurasian Patent Organization

VANCOUVER, BC / October 30, 2025 / BioNxt Solutions Inc. (“BioNxt” or the “Company”) (CSE:BNXT)(OTCQB:BNXTF)(FSE:BXT), a bioscience innovator specializing in advanced drug delivery systems, is...

BNXT.CN : 0.5700 (-3.39%)
BNXTF : 0.4305 (-5.45%)
BioNxt Enters the Final Stretch Before Human Trials for Next-Generation MS Drug

BioNxt Solutions Inc. (CSE:BNXT) (OTCQB:BNXTF) (FSE:BXT), a bioscience company developing next-generation drug delivery technologies, has launched a 15-day dosing optimization study for its lead product...

BNXT.CN : 0.5700 (-3.39%)
BNXTF : 0.4305 (-5.45%)
BioNxt Launches 15-day Sublingual Cladribine Dosing Optimization Study in Preparation for Human Bioequivalence Study

VANCOUVER, BC / October 21, 2025 / BioNxt Solutions Inc. (“BioNxt” or the “Company”) (CSE:BNXT)(OTCQB:BNXTF)(FSE:BXT), a bioscience innovator specializing in next-generation drug delivery technologies,...

BNXT.CN : 0.5700 (-3.39%)
BNXTF : 0.4305 (-5.45%)
BioNxt Solutions Announces Delay In Filing 2024 Annual Financial Statements

VANCOUVER, BC / ACCESS Newswire / May 1, 2025 / BioNxt Solutions Inc. ("BioNxt" or the "Company") (CSE:BNXT)(OTC:BNXTF)(FSE:BXT), announces that its annual financial statements for the year ended December...

BNXT.CN : 0.5700 (-3.39%)
BNXTF : 0.4305 (-5.45%)
BioNxt Solutions Prepares for Human Bioequivalence Study For MS

VANCOUVER, BC / ACCESS Newswire / April 23, 2025 / BioNxt Solutions Inc. ("BioNxt" or the "Company") (CSE:BNXT)(OTC PINK:BNXTF)(FSE:BXT), a bioscience innovator specializing in advanced drug delivery systems,...

BNXT.CN : 0.5700 (-3.39%)
BNXTF : 0.4305 (-5.45%)
BioNxt Solutions Announces Closing of Final Tranche of Fully Subscribed Convertible Debenture Unit Private Placement

NOT FOR DISTRIBUTION TO UNITED STATES NEWS WIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES

BNXT.CN : 0.5700 (-3.39%)
BNXTF : 0.4305 (-5.45%)
BioNxt Solutions Announces Closing of First Tranche of Convertible Debenture Unit Private Placement

NOT FOR DISTRIBUTION TO UNITED STATES NEWS WIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES

BNXT.CN : 0.5700 (-3.39%)
BNXTF : 0.4305 (-5.45%)
BioNxt Solutions Announces Debenture Unit Financing

NOT FOR DISTRIBUTION TO UNITED STATES NEWS WIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES

BNXT.CN : 0.5700 (-3.39%)
BNXTF : 0.4305 (-5.45%)
Clarification of Promotional Activities

VANCOUVER, BC / ACCESS Newswire / February 21, 2025 / BioNxt Solutions Inc. ("BioNxt" or the "Company") (CSE:BNXT)(OTC PINK:BNXTF)(FSE:4XT) reports a clarification to its news release dated January 31,...

BNXT.CN : 0.5700 (-3.39%)
BNXTF : 0.4305 (-5.45%)

Barchart Exclusives

This Penny Stock Is Soaring on a New Drone Contract Win. Should You Buy Peraso Here Amid U.S.-Iran War?
Peraso stock soars on a new defense contract from InTACT. But does that warrant buying PRSO shares in 2026? Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar